Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118080 | 0.92 | DRD2 (0.49) | DRD2CACNA1HSIGMAR1TDP1EPHX1 | |
| SCHEMBL31301242 | 0.92 | DRD2 (0.63) | DRD2CACNA1HSIGMAR1TDP1EPHX1 | |
| SCHEMBL8406122 | 0.91 | DRD2 (0.54) | DRD2CACNA1HSIGMAR1TDP1MAOA | |
| SCHEMBL4119702 | 0.91 | EPHX1 (0.49) | DRD2CACNA1HSIGMAR1TDP1EPHX1 | |
| SCHEMBL9093109 | 0.88 | CD274 (0.53) | DRD2CACNA1HTDP1CD274 | |
| SCHEMBL16941149 | 0.88 | MEN1 (0.47) | DRD2CACNA1HSIGMAR1TDP1EPHX1 | |
| SCHEMBL30380723 | 0.88 | DRD2 (0.54) | DRD2CACNA1HSIGMAR1TDP1EPHX1 | |
| SCHEMBL25716981 | 0.88 | DRD2 (0.54) | DRD2CACNA1HSIGMAR1TDP1EPHX1 | |
| SCHEMBL13202614 | 0.87 | DRD2 (0.59) | DRD2CACNA1HSIGMAR1TDP1ALDH1A1 | |
| SCHEMBL5324032 | 0.86 | DRD2 (0.57) | DRD2CACNA1HSIGMAR1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023383-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-02 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-10953095-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-03-23 | — | — | US | disclosed |
| US-20200138955-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-05-07 | — | — | US | disclosed |
| US-10456473-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-10-29 | — | — | US | disclosed |
| US-20180104342-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-19 | — | — | US | disclosed |
| US-9694077-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-07-04 | — | — | US | disclosed |
| EP-3097908-A1 | LIPID COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2016-11-30 | — | — | EP | disclosed |
| US-20150190515-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2015-07-09 | — | — | US | disclosed |
| US-8883202-B2 | Lipid compositions | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-11-11 | — | — | US | disclosed |
| WO-2010129709-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953095-B2 | Lipid compositions | SGMS1, LIPA, SGMS2 | DRD2 3276/4885CACNA1H 4399/4885SIGMAR1 754/4885 |
| US-20180104342-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | DRD2 3276/4885CACNA1H 4399/4885SIGMAR1 754/4885 |
| US-20150190515-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | DRD2 3276/4885CACNA1H 4399/4885SIGMAR1 754/4885 |
| US-10456473-B2 | Lipid compositions | SGMS1, LIPA, SGMS2 | DRD2 3276/4885CACNA1H 4399/4885SIGMAR1 754/4885 |
| US-20240066129-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | DRD2 3526/4885CACNA1H 4390/4885SIGMAR1 693/4885 |
| US-12023383-B2 | Lipid compositions | SGMS1, SGMS2, LIPA | DRD2 3526/4885CACNA1H 4390/4885SIGMAR1 693/4885 |
| US-20200138955-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | DRD2 3276/4885CACNA1H 4399/4885SIGMAR1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.